Pharmaceutical Sector

DGCI sends Notice to Glenmark Pharmaceuticals over antiviral drug FabiFlu for COVID-19 Patients

DGCI sends Notice to Glenmark Pharmaceuticals over antiviral drug FabiFlu for COVID-19 Patients

Glenmark Pharmaceuticals has received a notice from the Drugs Controller General of India (DGCI) regarding pricing of antiviral drug FabiFlu that has been effective is recovery of some COVID-19 pat

Controversy about Gilead’s Remdesivir in India due to low production and black market sale

Controversy about Gilead’s Remdesivir in India due to low production and black market sale

Gilead Sciences signed a contract with four Indian pharmaceutical companies to produce its medication ‘Remdesivir’ which has been found effective in treatment of some COVID-19 patients.

Dr Reddy’s reports 22 percent Growth in Profit before Tax

Dr Reddy’s reports 22 percent Growth in Profit before Tax

Pharmaceutical major Dr Reddy’s has reported 22 percent jump in profit before tax for fourth quarter and 10 percent growth in revenue.

Gilead Sciences CEO aims at widely available Coronavirus Treatment

Gilead Sciences CEO aims at widely available Coronavirus Treatment

Gilead Sciences CEO Daniel O’Day said on Friday that the company is focused on experimental coronavirus drug that is affordable and widely accessible.

Ashwani Gujral: BUY Maruti Suzuki, Axis Bank, Dr Reddy’s, Cadila Healthcare and Hindalco

Ashwani Gujral: BUY Maruti Suzuki, Axis Bank, Dr Reddy’s, Cadila Healthcare and Hindalco

Market analyst Ashwani Gujral is bullish for the day with five BUY Calls for stocks.

BUY Abbott India for Long Term: Nirali Shah, SAMCO Research

BUY Abbott India for Long Term: Nirali Shah, SAMCO Research

ABBOTT India is a good long term investment for Indian investors as per Nirali Shah, SAMCO Research.

Pages